Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last days
Enjoy this offer
* See conditions under "Our services"

Valuation: CARMAT

Market Cap 61.46L 71.16L 56.63L 53.01L 99.35L 68Cr 1.01Cr 6.69Cr 2.61Cr 33Cr 2.67Cr 2.61Cr 113.99Cr P/E Ratio 2023
-3.09x
P/E Ratio 2024 -0.95x
Enterprise Value 5.92Cr 6.86Cr 5.46Cr 5.11Cr 9.58Cr 652Cr 9.73Cr 64Cr 25Cr 317.35Cr 26Cr 25Cr 1.1TCr EV / Sales 2023
56.1x
EV / Sales 2024 13.5x
Free-Float
89.06%
Yield 2023 *
-
Yield 2024 -
Manager TitleAgeSince
Chief Executive Officer 55 01/09/2016
Director of Finance/CFO - 12/12/2018
Chief Tech/Sci/R&D Officer - 01/04/2025
Director TitleAgeSince
Director/Board Member 55 -
Director/Board Member 68 02/01/2017
Director/Board Member 79 20/04/2017
Change 5-day change 1-year change 3-year change Capi.($)
-50.96%-54.87% - - 70.8L
+2.15%+2.14%-17.95%+11.53% 12TCr
-0.31%+0.04%+1.12%-5.11% 1.29TCr
+2.05%+1.45%+29.93%+89.47% 729.48Cr
+1.87%-3.51%-46.74%-69.06% 411.68Cr
+2.06%+5.59%+11.04%+33.01% 249.16Cr
+5.46%+10.30%-16.96%-14.78% 170.1Cr
+1.67%-6.39%+3.63%-11.43% 163.04Cr
-8.89%-8.45%+165.17%+112.14% 148.75Cr
Average -4.97%+1.07%+16.16%+18.22% 1.86TCr
Weighted average by Cap. +1.86%+1.39%-12.18%+12.50%

Financials

2023 2024
Net sales 38.37L 44.43L 35.36L 33.1L 62.03L 42Cr 62.99L 4.17Cr 1.63Cr 21Cr 1.67Cr 1.63Cr 71Cr 73.44L 85.03L 67.67L 63.35L 1.19Cr 81Cr 1.21Cr 7.99Cr 3.12Cr 39Cr 3.19Cr 3.12Cr 136.21Cr
Net income -5.39Cr -6.24Cr -4.96Cr -4.65Cr -8.71Cr -592.83Cr -8.84Cr -59Cr -23Cr -288.55Cr -23Cr -23Cr -999.11Cr -5.14Cr -5.95Cr -4.74Cr -4.43Cr -8.31Cr -565.6Cr -8.44Cr -56Cr -22Cr -275.3Cr -22Cr -22Cr -953.23Cr
Net Debt 4.96Cr 5.75Cr 4.57Cr 4.28Cr 8.02Cr 546.25Cr 8.15Cr 54Cr 21Cr 265.88Cr 22Cr 21Cr 920.6Cr 5.31Cr 6.15Cr 4.89Cr 4.58Cr 8.58Cr 584.37Cr 8.72Cr 58Cr 23Cr 284.43Cr 23Cr 23Cr 984.85Cr
Logo CARMAT
Carmat SA, formerly known as Carmat SAS is a France-based company engaged in the development and production of heart prosthesis. The Company is developing an orthotopic and biocompatible artificial heart which works like a natural heart, and which is hydraulically activated. It specializes in the development of a fully implantable orthotopic artificial heart, its electrical power supply system, and its telediagnosis system. The Company formed a network of partnerships with hospitals and various scientific companies, such as The Georges Pompidou European Hospital, The Marie Lannelongue Surgical Center, The Hospital Charles Nicolle of Rouen, Dedienne Sante, PaxiTech, Vignal Artru Industries, French Vessels, and Blood Institute, Laboratoire de Recherche Biochirurgicale and others.
Employees
153
- 40% : Our Best Subscriber-Only Tools to Spot Tomorrow’s Top Investments!
d
:
:
SEIZE THE OFFER!